Oncology News | pharmaphorum

News

Kiadis Pharma and Sanofi to unlock power of natural killer c...

Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells with the French pharma’s blood cancer antibody Sarcl

News

EU regulators approve AstraZeneca's Lynparza in pancreatic c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation.

News

AI health record scanning could identify pancreatic cancer e...

Artificial intelligence (AI) could hold the key to identifying people at risk of pancreatic cancer early, allowing them to start potentially life-saving treatment more quickly.

News

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A

News

Merck & Co's Keytruda gets new colorectal cancer use after m...

It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal cancer patients with certain mutations, and th

News

NICE green lights Roche’s Rozlytrek for NTRK tumours

The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid tumours, shortly after clearing a rival drug from

Kiadis Pharma and Sanofi to unlock power of natural killer c...

EU regulators approve AstraZeneca's Lynparza in pancreatic c...

AI health record scanning could identify pancreatic cancer e...

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

Merck & Co's Keytruda gets new colorectal cancer use after m...

NICE green lights Roche’s Rozlytrek for NTRK tumours

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks